Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Downward Trends in Proteomics Deal Making

This article was originally published in Start Up

Executive Summary

For more than a year, VCs have backed away from the proteomics tools group--drug companies hadn't signed the expected number and value of deals with them, and it was deal revenues that were, according to most business plans, going to support these start-ups. That pharma and biotech companies have a bigger appetite for products than for platform technology has become a truism. Licensors increasingly are finding that they must offer partners more than a discovery technology platform-either by validating targets and building value before out-licensing, or at least having the biological capability in-house to be a true collaborator.

You may also be interested in...



Genomica Gives Up the Ghost

Less than two months after Genomica announced a change in strategic direction, resulting from disappointing market penetration of its third-party enterprise bioinformatics software, the company agreed to be acquired by Exelixis for $110 million in stock--precisely the amount of cash it was sitting on, making the deal in essence a back-door follow-on offering for Exelixis. The acquirer is therefore getting Genomica's software and technology base for a song, a fact that speaks volumes about the sustainability of a software-based bioinformatics business.

The Proteomics Challenge

The fact that proteomic diversity is most likely several logs greater than genomic diversity is only one reason why moving from gene expression-based analyses to proteomics-based drug development presents a daunting challenge. The large issues go well beyond protein isolation and characterization: Genomics simply doesn't tell you how proteins function in vivo, and companies are just now beginning to amass and integrate the tools to correlate protein structure and function. In many ways, proteomics heralds the second coming of rational drug design, enabled now by high-throughput tools and the algorithms of computational biology. But whether structure-guided drug development will prove to be efficient or cost-effective remains to be seen.

Science Matters: With Ferroptosis, Cancer Drug Developers Can Strike While Iron Is Hot

A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel